Pfizer’s (PFE) Overweight Rating Reiterated at Cantor Fitzgerald
Cantor Fitzgerald reaffirmed their overweight rating on shares of Pfizer (NYSE:PFE – Free Report) in a report published on Monday, Benzinga reports. They currently have a $45.00 price target on the biopharmaceutical company’s stock. A number of other brokerages have also recently commented on PFE. UBS Group increased their price target on Pfizer from $30.00 […]
More Stories
Bessent Urges Half-Point September Interest-Rate Cut, Targets at Least 1.5 Percent Total Easing
By Tom Ozimek Treasury Secretary Scott Bessent is urging the Federal Reserve to slash interest rates by half a percentage...
Cooperstown’s Baseball Museum a Must Visit Annually for Hall of Famer Jenkins
By Donald Laible For more than 30 years, Baseball Hall of Famer Ferguson Jenkins has been grateful for his annual...
The Metrics Behind Game Design: How Data Shapes the Way We Play
Game designing is an art. Before a gamer gets to enjoy the characters and the narrative, it is essential for...
What Happens When Your Advice Backfires? The Risk of Being ‘Almost Right’
There’s a strange kind of confidence that creeps in when you’ve built your career on giving advice. If there’s anything...
One Piece Season 2: Release Date, Trailer, Cast, and Other Announcements
One Piece season 2 is expected to be released in 2026, as the shooting was completed in early 2025. For...
Perplexity AI Wants to Buy Google Chrome for $34.5 Billion!
A young artificial intelligence company called Perplexity AI has surprised the tech world by offering $34.5 billion to buy Google...